EP3849534
Samsetning af dasatíníb og adagrasíb til notkunar við meðhöndlun á ekki-smáfrumu lungnakrabbameini
:
EP einkaleyfi í gildi á Íslandi:
9.9.2019:
5.3.2025:
19858883.2
:
7.5.2025:
15.6.2025
:
8.9.2039:
8.9.2025
:
COMBINATION OF DASATINIB AND ADAGRASIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
9.9.2019
5.3.2025
7.5.2025
15.6.2025
8.9.2025
:
Mirati Therapeutics, Inc.:
Route 206 and Province Line Road, Princeton, New Jersey 08543, US
:
ENGSTROM, Lars, Daniel:
Carlsbad, CA 92009, US
:
ARANDA, Ruth, Wei:
San Diego, CA 92108, US
:
OLSON, Peter:
San Diego, CA 92122, US
:
CHRISTENSEN, James, Gail:
San Diego, CA 92130, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201862729169 P:
10.9.2018:
US
:
US2019050224:
9.9.2019
:
A61K 31/5025, A61K 31/506, A61K 31/517, A61K 31/519, A61K 31/5377, A61K 31/541, A61K 31/553, A61K 45/06, A61P 35/00, A61P 35/02, A61K 9/00